Drugs / bi-4SCAR PSMA/CD70 T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05437341 | Jun → Dec 2026 expected | cancer | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bi-4SCAR PSMA/CD70 T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05437341 ↗ |
| Action | Deplete | “enable the T cells to recognize and kill tumor cells” NCT05437341 ↗ |
| Modality | Cell therapy | “T cells genetically modified to express a 4th generation lentiviral anti-PSMA/CD70 bi-specific chimeric antigen receptor” NCT05437341 ↗ |
| Route | Intravenous | “via IV” NCT05437341 ↗ |